Cancer

January 8, 2018

Molecular therapy for Metastatic cancers: Torasemide, an anti-hypertensive drug, increases the expression of tumor/metastasis suppressors CCM3/KRIT1 and TIMP3, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 8/January/2017, 10.48 pm

Molecular therapy for Metastatic cancers: Torasemide, an anti-hypertensive drug, increases the expression of tumor/metastasis suppressors CCM3/KRIT1 and TIMP3, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 8/January/2017, 10.48 pm https://genomediscovery.org/wp-content/uploads/2018/01/Torasemide-increases-the-exp-of-metastatic-suppressor-CCM3-and-TIMP3-and-attenuates-metastatic-progression.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/01/Torasemide-increases-the-exp-of-metastatic-suppressor-CCM3-and-TIMP3-and-attenuates-metastatic-progression.jpg January 8, 2018 January 8, 2018

From Significance of the study to Public health relevance: Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

January 7, 2018

Molecular therapy for Metastatic cancers: Torasemide, an anti-hypertensive drug, increases the expression of tumor suppressors TPM1 and TAp63, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 7/January/2017, 11.17 pm

Molecular therapy for Metastatic cancers: Torasemide, an anti-hypertensive drug, increases the expression of tumor suppressors TPM1 and TAp63, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 7/January/2017, 11.17 pm https://genomediscovery.org/wp-content/uploads/2018/01/Torasemide-increases-the-exp-of-metastatic-suppressor-TPM1-and-TP63-and-attenuates-metastatic-progression.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/01/Torasemide-increases-the-exp-of-metastatic-suppressor-TPM1-and-TP63-and-attenuates-metastatic-progression.jpg January 7, 2018 January 7, 2018

From Significance of the study to Public health relevance: Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

December 23, 2017

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Pravastatin, Herbimycin, Temozolomide, Zebularine, Salinomycin, and Clomipiramine (PHTZSC) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 24/December/2017, 12.42 am

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Pravastatin, Herbimycin, Temozolomide, Zebularine, Salinomycin, and Clomipiramine (PHTZSC) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 24/December/2017, 12.42 am https://genomediscovery.org/wp-content/uploads/2017/12/PHTZSC-inhibits-the-expression-of-EGFR-and-Bcl2-xl-increases-p53-protein-levels-inhibits-a-number-of-immune-evasion-molecules-and-thereby-inhibits-GBM-progression.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/12/PHTZSC-inhibits-the-expression-of-EGFR-and-Bcl2-xl-increases-p53-protein-levels-inhibits-a-number-of-immune-evasion-molecules-and-thereby-inhibits-GBM-progression.jpg December 23, 2017 December 23, 2017

Introduction:What they say: A recent study from Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA; Jonsson Comprehensive Cancer Center, David Geffen UCLA…

December 15, 2017

Natural product-derived therapy for enhancing anti-cancer immunity: Andrographolide, isolated from Andrographis paniculata, decreases the level of LATS1/2 (large tumor suppressor 1 and 2), increases immunogenicity of tumors, enhances anti-tumor immune responses, and inhibits tumor growth via down regulation of its target gene, 16/December/2017, 12.29 am

Natural product-derived therapy for enhancing anti-cancer immunity: Andrographolide, isolated from Andrographis paniculata, decreases the level of LATS1/2 (large tumor suppressor 1 and 2), increases immunogenicity of tumors, enhances anti-tumor immune responses, and inhibits tumor growth via down regulation of its target gene, 16/December/2017, 12.29 am https://genomediscovery.org/wp-content/uploads/2017/12/Andrographolide-increases-Cytotoxic-T-cell-and-B-cell-activity-enhances-anti-tumor-immunity-and-efficacy-through-down-regulation-of-LATS1-and-LATS21.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/12/Andrographolide-increases-Cytotoxic-T-cell-and-B-cell-activity-enhances-anti-tumor-immunity-and-efficacy-through-down-regulation-of-LATS1-and-LATS21.jpg December 15, 2017 December 15, 2017

Introduction: What they say: A study from the Department of Pharmacology and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA shows that “The Hippo Pathway Kinases LATS1/2…

December 15, 2017

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Gedunine, Dianhydrogalactitol, EGCG, Salinomycin, Simvastatin and Fluoxetine (GDESSF) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 15/December/2017, 11.23 pm

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Gedunine, Dianhydrogalactitol, EGCG, Salinomycin, Simvastatin and Fluoxetine (GDESSF) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 15/December/2017, 11.23 pm https://genomediscovery.org/wp-content/uploads/2017/12/GDESSF-inhibits-the-expression-of-EGFR-and-Bcl2-xl-increases-p53-protein-levels-inhibits-a-number-of-immune-evasion-molecules.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/12/GDESSF-inhibits-the-expression-of-EGFR-and-Bcl2-xl-increases-p53-protein-levels-inhibits-a-number-of-immune-evasion-molecules.jpg December 15, 2017 December 15, 2017

December 8, 2017

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Desipramine, Evodiamine, Atorvastatin, Hypericin, Salinomycin and Temozolomide (DEAHSAT) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 8/December/2017, 10.24 pm

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Desipramine, Evodiamine, Atorvastatin, Hypericin, Salinomycin and Temozolomide (DEAHSAT) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 8/December/2017, 10.24 pm https://genomediscovery.org/wp-content/uploads/2017/12/Despiramine-Evodiamine-Atorvastatin-Hypercin-Salinomycin-and-Temozolomide-DEAHSAT-inhibit-the-expression-of-EGFR-and-Bcl2-xl-increase-p53-protein-levels-1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/12/Despiramine-Evodiamine-Atorvastatin-Hypercin-Salinomycin-and-Temozolomide-DEAHSAT-inhibit-the-expression-of-EGFR-and-Bcl2-xl-increase-p53-protein-levels-1.jpg December 8, 2017 December 9, 2017

Popular Post